NovoCure Limited (NVCR) Stock
NSQ · NVCR
16.69
Fundamentals
Market cap
$1.94B
Price / Earnings ratio
-13.1x
Price / Sales ratio
2.8x
Price / Book ratio
5.8x
Return on assets
-0.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
SectorHealthcare
IndustryMedical Devices
Employees1,605
CEOMr. Frank Leonard
IPO DateOct 2, 2015
HeadquartersBaar, Switzerland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. William F. Doyle | Executive Chairman | 1962 |
| Mr. Frank Leonard | CEO & Director | — |
| Mr. Christoph Brackmann | Chief Financial Officer | 1974 |
| Mr. Michael Puri | Chief Human Resources Officer | 1969 |
| Dr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer & Chief Medical Officer | 1978 |
| Mr. Mukund Paravasthu | Chief Operating Officer | 1970 |
| Mr. Adam Daney | Head of Investor Relations | — |
| Mr. Barak Ben-Arye | General Counsel | 1977 |
Fundamentals
Valuation
Market cap$1.94B
Price-to-sales ratio2.78
Price-to-book value5.76
Price-earnings ratio-13.10
Return on Equity-51.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio-0.47
Earnings Per Share
Earnings Per Share$-1.30
Income Statement
Average volume1,265,066
EBITDA$-167.91M
1 year high (52w)$21.45
1 year low (52w)$9.82
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



